Lenvima (lenvatinib capsules) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has unresectable or metastatic melanoma
• The medication is used in combination with Keytruda (pembrolizumab intravenous injection)
• Patient has disease progression on anti-PD-1/PD-L1-based therapy

Approval duration

1 year